Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Clinical use and applications of histone deacetylase inhibitors in multiple myelomaNovel strategies to target the ubiquitin proteasome system in multiple myelomaPanobinostat for the treatment of multiple myeloma: the evidence to dateDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveSuberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideA novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.Panobinostat: a review of trial results and future prospects in multiple myeloma.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myelomaEpigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.Computational modeling of methionine cycle-based metabolism and DNA methylation and the implications for anti-cancer drug response prediction.EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.
P2860
Q26740359-48BE5780-42EC-4339-BB8D-F2D1731AFE1CQ26745930-D5087CB5-A916-4E8D-9A44-4E257F9979B1Q26773246-3DA76D58-EE92-4B3F-ACCD-9E9D7F6BF154Q26778674-2197311C-31F1-4EF7-A662-3F70FF32D784Q27692033-19C4B7BC-55CA-41F1-A5F0-79877B7DBEE1Q28069789-B3920796-5613-4194-9EE3-AD8D3CD9A1C2Q30303153-935C4D7D-C10E-4E53-BA27-AEF62D50BF08Q34103053-0C577AEA-A14E-40B6-8646-F389789E99ADQ34602263-F236653F-FAB4-48E8-AF8F-7705F58C1C3BQ36544516-D3999F5F-81BD-46ED-A016-A551C98D1987Q37389377-2439B7F3-16B6-403F-8DB6-FC73D9E49EFCQ37408128-9F6187DE-1EBB-4AC4-95E7-9507EEA72FBDQ38269612-A87A0481-9C08-4E5E-A7D7-97F2DED9A80CQ38910971-126646B3-F073-4118-B546-D1DCCABB99A4Q38967891-0537A37D-CFA6-4C71-97FE-A6ADC5830F9EQ39021977-6BDCC342-8095-4216-881C-87FAE96FF3DAQ39137683-DFDD0D06-BA99-4D24-ACC4-F2142985FEDFQ42459032-5DC130FF-8344-428D-BDB6-BFD74D11BDCBQ52676395-A23226ED-C57E-4FFE-8FCE-E75AF67FC0B6Q55010005-210B2A72-C539-4C21-BB6F-DD8D3EEF56A9Q55018505-FA507477-5C48-4E84-8A63-C810DA2FC3A0
P2860
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
@en
type
label
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
@en
prefLabel
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
@en
P2093
Elke De Bruyne
Els Van Valckenborgh
Ivan Van Riet
Karin Vanderkerken
P2860
P304
P356
10.3390/CANCERS5020430
P577
2013-04-15T00:00:00Z